In Section C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will obtain treatment right until condition progression or even the individuals are not able to tolerate the study drugs. For all move cytometry experiments, ten,000 cells for every replicate were https://abbv-744inacutemyeloidleu24578.pages10.com/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-67470892